LiverLearning®: 2019 Webinar: Challenges in Antiviral Therapy for Hepatitis C

Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Stuart C. Gordon Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital.

Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations

Michelle A. Camarata, Aftab Ala, Michael L. Schilsky – 23 July 2019 – We evaluate Wilson disease (WD) treatment with zinc acetate (U.S. Food and Drug Administration approved) and alternative zinc salts. Studies examining zinc therapy in WD are few, and data on alternative zinc salts are limited. We describe one of the largest recent studies of zinc therapy in WD.

A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice

Xiaobo Wang, Mark R. Sommerfeld, Kerstin Jahn‐Hofmann, Bishuang Cai, Aveline Filliol, Helen E. Remotti, Robert F. Schwabe, Aimo Kannt, Ira Tabas – 23 July 2019 – Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue and is associated with significant liver‐related morbidity and mortality. At present, there are no approved drug therapies for NASH.

Subscribe to